Products

(+)-(3R,5S), tert-Butyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenate, also known as R1.5 or tert-butyl-rosuvastatin, is a chemical compound with potential applications in the pharmaceutical industry.Rosuvastatin is a well-known cholesterol-lowering medication that belongs to a class of drugs called statins. It works by inhibiting an enzyme called HMG-CoA reductase, which is involved in the production of cholesterol in the body. R1.5 is a derivative of rosuvastatin that contains a tert-butyl group attached to the molecule, providing additional properties and potential benefits.One possible application of R1.5 is as a pharmaceutical ingredient for the treatment of hyperlipidemia and prevention of cardiovascular diseases. Like rosuvastatin, R1.5 can be used to lower levels of LDL cholesterol, also known as "bad" cholesterol, and triglycerides in the blood. This compound may exhibit improved pharmacokinetic properties, such as increased bioavailability or enhanced stability, compared to the parent drug. Furthermore, the tert-butyl group may contribute to the compound's solubility and formulation versatility, making it suitable for various drug delivery systems.Another potential use of R1.5 is in the development of prodrugs or targeted drug delivery systems. The tert-butyl group can act as a protective group, allowing for controlled release of rosuvastatin in specific tissues or organs, such as the liver. This strategy can enhance the drug's efficacy and minimize potential side effects by increasing its concentration at the target site while reducing exposure to non-target tissues.Additionally, R1.5 can serve as a valuable tool for medicinal chemists in drug discovery and development. The compound's complex structure provides a platform for further modifications and derivatizations. Researchers can utilize R1.5 as a lead compound to explore structure-activity relationships and develop new analogs with enhanced potency, selectivity, or improved therapeutic profiles. Such studies may contribute to the development of novel and more effective statins or other cholesterol-lowering agents.In conclusion, (+)-(3R,5S), tert-Butyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenate (R1.5 or tert-butyl-rosuvastatin) holds promise as a pharmaceutical compound for the treatment of hyperlipidemia and cardiovascular diseases. Its unique structure, combined with the tert-butyl group, may provide advantages such as improved pharmacokinetics, targeted drug delivery, and opportunities for further drug development. Further research and development are needed to fully explore the potential of R1.5 in the pharmaceutical field.